MovDisordV3, PascalFrancis, Corpus, bibRecord, 000559

Meta-Analysis of 123I-MIBG Cardiac Scintigraphy for the Diagnosis of Lewy Body-Related Disorders

Identifieur interne : 000559 ( PascalFrancis/Corpus ); précédent : 000558; suivant : 000560

Meta-Analysis of 123I-MIBG Cardiac Scintigraphy for the Diagnosis of Lewy Body-Related Disorders

Auteurs : Alisha E. King ; Jim Mintz ; Donald R. Royall

Source :

Movement disorders [ 0885-3185 ] ; 2011.

RBID : Pascal:11-0321200

Descripteurs français

Pascal (Inist)
- Démence à corps de Lewy, Maladie de Parkinson, Atrophie multisystématisée, Démence d'Alzheimer, Pathologie du système nerveux, Scintigraphie, Diagnostic, Corps Lewy, Parasomnie.

English descriptors

KwdEn :
- Alzheimer disease, Diagnosis, Lewy body, Lewy body dementia, Multiple system atrophy, Nervous system diseases, Parasomnia, Parkinson disease, Scintigraphy.

Abstract

Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac ¹²³I-metaiodobenzylguanidine uptake in Lewy body-related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered ¹²³I-metaiodobenzylguanidine cardiac scintigraphy a "supportive" diagnostic feature, based on limited evidence. We report a meta-analysis of the literature and an assessment of the utility of ¹²³I-metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty-six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed-effects regression model was used to analyze the delayed mean heart-to-mediastinum ratio of ¹²³I-metaiodobenzylguanidine uptake. ¹²³I-metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder ; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart-to-mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. ¹²³I-metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 26`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Meta-Analysis of ¹²³I-MIBG Cardiac Scintigraphy for the Diagnosis of Lewy Body-Related Disorders`
A11	`01`	`1`		`@1 KING (Alisha E.)`
A11	`02`	`1`		`@1 MINTZ (Jim)`
A11	`03`	`1`		`@1 ROYALL (Donald R.)`
A14	`01`			`@1 Department of Psychiatry, University of Texas Health Science Center at San Antonio @2 San Antonio, Texas @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A14	`02`			`@1 Department of Medicine, University of Texas Health Science Center at San Antonio @2 San Antonio, Texas @3 USA @Z 3 aut.`
A14	`03`			`@1 Department of Pharmacology, University of Texas Health Science Center at San Antonio @2 San Antonio, Texas @3 USA @Z 3 aut.`
A14	`04`			`@1 Department of Family & Community Medicine, University of Texas Health Science Center at San Antonio @2 San Antonio, Texas @3 USA @Z 3 aut.`
A14	`05`			`@1 South Texas Veterans' Health System, Audie L. Murphy Division GRECC @2 San Antonio, Texas @3 USA @Z 3 aut.`
A20				`@1 1218-1224`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000190480410050`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 31 ref.`
A47	`01`	`1`		`@0 11-0321200`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac ¹²³I-metaiodobenzylguanidine uptake in Lewy body-related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered ¹²³I-metaiodobenzylguanidine cardiac scintigraphy a "supportive" diagnostic feature, based on limited evidence. We report a meta-analysis of the literature and an assessment of the utility of ¹²³I-metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty-six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed-effects regression model was used to analyze the delayed mean heart-to-mediastinum ratio of ¹²³I-metaiodobenzylguanidine uptake. ¹²³I-metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder ; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart-to-mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. ¹²³I-metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Démence à corps de Lewy @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Lewy body dementia @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Demencia cuerpos Lewy @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Atrophie multisystématisée @2 NM @5 03`
C03	`03`	`X`	`ENG`	`@0 Multiple system atrophy @2 NM @5 03`
C03	`03`	`X`	`SPA`	`@0 Atrofia multisistematizada @2 NM @5 03`
C03	`04`	`X`	`FRE`	`@0 Démence d'Alzheimer @5 04`
C03	`04`	`X`	`ENG`	`@0 Alzheimer disease @5 04`
C03	`04`	`X`	`SPA`	`@0 Demencia Alzheimer @5 04`
C03	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 05`
C03	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 05`
C03	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 05`
C03	`06`	`X`	`FRE`	`@0 Scintigraphie @5 09`
C03	`06`	`X`	`ENG`	`@0 Scintigraphy @5 09`
C03	`06`	`X`	`SPA`	`@0 Centelleografía @5 09`
C03	`07`	`X`	`FRE`	`@0 Diagnostic @5 10`
C03	`07`	`X`	`ENG`	`@0 Diagnosis @5 10`
C03	`07`	`X`	`SPA`	`@0 Diagnóstico @5 10`
C03	`08`	`X`	`FRE`	`@0 Corps Lewy @5 11`
C03	`08`	`X`	`ENG`	`@0 Lewy body @5 11`
C03	`08`	`X`	`SPA`	`@0 Cuerpo Lewy @5 11`
C03	`09`	`X`	`FRE`	`@0 Parasomnie @2 NM @5 12`
C03	`09`	`X`	`ENG`	`@0 Parasomnia @2 NM @5 12`
C03	`09`	`X`	`SPA`	`@0 Parasomnio @2 NM @5 12`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Maladie dégénérative @5 38`
C07	`02`	`X`	`ENG`	`@0 Degenerative disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 38`
C07	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 39`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 41`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 41`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 41`
C07	`05`	`X`	`FRE`	`@0 Trouble du sommeil @5 42`
C07	`05`	`X`	`ENG`	`@0 Sleep disorder @5 42`
C07	`05`	`X`	`SPA`	`@0 Trastorno sueño @5 42`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 43`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 43`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 43`
N21				`@1 220`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0321200 INIST
ET :	Meta-Analysis of ¹²³I-MIBG Cardiac Scintigraphy for the Diagnosis of Lewy Body-Related Disorders
AU :	KING (Alisha E.); MINTZ (Jim); ROYALL (Donald R.)
AF :	Department of Psychiatry, University of Texas Health Science Center at San Antonio/San Antonio, Texas/Etats-Unis (1 aut., 2 aut., 3 aut.); Department of Medicine, University of Texas Health Science Center at San Antonio/San Antonio, Texas/Etats-Unis (3 aut.); Department of Pharmacology, University of Texas Health Science Center at San Antonio/San Antonio, Texas/Etats-Unis (3 aut.); Department of Family & Community Medicine, University of Texas Health Science Center at San Antonio/San Antonio, Texas/Etats-Unis (3 aut.); South Texas Veterans' Health System, Audie L. Murphy Division GRECC/San Antonio, Texas/Etats-Unis (3 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2011; Vol. 26; No. 7; Pp. 1218-1224; Bibl. 31 ref.
LA :	Anglais
EA :	Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac ¹²³I-metaiodobenzylguanidine uptake in Lewy body-related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered ¹²³I-metaiodobenzylguanidine cardiac scintigraphy a "supportive" diagnostic feature, based on limited evidence. We report a meta-analysis of the literature and an assessment of the utility of ¹²³I-metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty-six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed-effects regression model was used to analyze the delayed mean heart-to-mediastinum ratio of ¹²³I-metaiodobenzylguanidine uptake. ¹²³I-metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder ; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart-to-mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. ¹²³I-metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies.
CC :	002B17; 002B17G
FD :	Démence à corps de Lewy; Maladie de Parkinson; Atrophie multisystématisée; Démence d'Alzheimer; Pathologie du système nerveux; Scintigraphie; Diagnostic; Corps Lewy; Parasomnie
FG :	Pathologie de l'encéphale; Maladie dégénérative; Pathologie du système nerveux central; Syndrome extrapyramidal; Trouble du sommeil; Trouble neurologique
ED :	Lewy body dementia; Parkinson disease; Multiple system atrophy; Alzheimer disease; Nervous system diseases; Scintigraphy; Diagnosis; Lewy body; Parasomnia
EG :	Cerebral disorder; Degenerative disease; Central nervous system disease; Extrapyramidal syndrome; Sleep disorder; Neurological disorder
SD :	Demencia cuerpos Lewy; Parkinson enfermedad; Atrofia multisistematizada; Demencia Alzheimer; Sistema nervioso patología; Centelleografía; Diagnóstico; Cuerpo Lewy; Parasomnio
LO :	INIST-20953.354000190480410050
ID :	11-0321200

Links to Exploration step

Pascal:11-0321200

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Meta-Analysis of <sup>123</sup>
I-MIBG Cardiac Scintigraphy for the Diagnosis of Lewy Body-Related Disorders</title>
<author><name sortKey="King, Alisha E" sort="King, Alisha E" uniqKey="King A" first="Alisha E." last="King">Alisha E. King</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mintz, Jim" sort="Mintz, Jim" uniqKey="Mintz J" first="Jim" last="Mintz">Jim Mintz</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Royall, Donald R" sort="Royall, Donald R" uniqKey="Royall D" first="Donald R." last="Royall">Donald R. Royall</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medicine, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Pharmacology, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Family & Community Medicine, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>South Texas Veterans' Health System, Audie L. Murphy Division GRECC</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0321200</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0321200 INIST</idno>
<idno type="RBID">Pascal:11-0321200</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000559</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Meta-Analysis of <sup>123</sup>
I-MIBG Cardiac Scintigraphy for the Diagnosis of Lewy Body-Related Disorders</title>
<author><name sortKey="King, Alisha E" sort="King, Alisha E" uniqKey="King A" first="Alisha E." last="King">Alisha E. King</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mintz, Jim" sort="Mintz, Jim" uniqKey="Mintz J" first="Jim" last="Mintz">Jim Mintz</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Royall, Donald R" sort="Royall, Donald R" uniqKey="Royall D" first="Donald R." last="Royall">Donald R. Royall</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medicine, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Pharmacology, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Family & Community Medicine, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>South Texas Veterans' Health System, Audie L. Murphy Division GRECC</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer disease</term>
<term>Diagnosis</term>
<term>Lewy body</term>
<term>Lewy body dementia</term>
<term>Multiple system atrophy</term>
<term>Nervous system diseases</term>
<term>Parasomnia</term>
<term>Parkinson disease</term>
<term>Scintigraphy</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Démence à corps de Lewy</term>
<term>Maladie de Parkinson</term>
<term>Atrophie multisystématisée</term>
<term>Démence d'Alzheimer</term>
<term>Pathologie du   système nerveux</term>
<term>Scintigraphie</term>
<term>Diagnostic</term>
<term>Corps Lewy</term>
<term>Parasomnie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac <sup>123</sup>
I-metaiodobenzylguanidine uptake in Lewy body-related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered <sup>123</sup>
I-metaiodobenzylguanidine cardiac scintigraphy a "supportive" diagnostic feature, based on limited evidence. We report a meta-analysis of the literature and an assessment of the utility of <sup>123</sup>
I-metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty-six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed-effects regression model was used to analyze the delayed mean heart-to-mediastinum ratio of <sup>123</sup>
I-metaiodobenzylguanidine uptake. <sup>123</sup>
I-metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder ; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart-to-mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. <sup>123</sup>
I-metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Meta-Analysis of <sup>123</sup>
I-MIBG Cardiac Scintigraphy for the Diagnosis of Lewy Body-Related Disorders</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KING (Alisha E.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MINTZ (Jim)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ROYALL (Donald R.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Psychiatry, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medicine, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Pharmacology, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Family & Community Medicine, University of Texas Health Science Center at San Antonio</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>South Texas Veterans' Health System, Audie L. Murphy Division GRECC</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>1218-1224</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000190480410050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>31 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0321200</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac <sup>123</sup>
I-metaiodobenzylguanidine uptake in Lewy body-related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered <sup>123</sup>
I-metaiodobenzylguanidine cardiac scintigraphy a "supportive" diagnostic feature, based on limited evidence. We report a meta-analysis of the literature and an assessment of the utility of <sup>123</sup>
I-metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty-six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed-effects regression model was used to analyze the delayed mean heart-to-mediastinum ratio of <sup>123</sup>
I-metaiodobenzylguanidine uptake. <sup>123</sup>
I-metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder ; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart-to-mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. <sup>123</sup>
I-metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Démence à corps de Lewy</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lewy body dementia</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Demencia cuerpos Lewy</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Atrophie multisystématisée</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Multiple system atrophy</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Atrofia multisistematizada</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Démence d'Alzheimer</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Alzheimer disease</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Demencia Alzheimer</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Scintigraphie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Scintigraphy</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Centelleografía</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Diagnostic</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Diagnosis</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Diagnóstico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Corps Lewy</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Lewy body</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Cuerpo Lewy</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Parasomnie</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Parasomnia</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Parasomnio</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Trouble du sommeil</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Sleep disorder</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Trastorno sueño</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>43</s5>
</fC07>
<fN21><s1>220</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0321200 INIST</NO>
<ET>Meta-Analysis of <sup>123</sup>
I-MIBG Cardiac Scintigraphy for the Diagnosis of Lewy Body-Related Disorders</ET>
<AU>KING (Alisha E.); MINTZ (Jim); ROYALL (Donald R.)</AU>
<AF>Department of Psychiatry, University of Texas Health Science Center at San Antonio/San Antonio, Texas/Etats-Unis (1 aut., 2 aut., 3 aut.); Department of Medicine, University of Texas Health Science Center at San Antonio/San Antonio, Texas/Etats-Unis (3 aut.); Department of Pharmacology, University of Texas Health Science Center at San Antonio/San Antonio, Texas/Etats-Unis (3 aut.); Department of Family & Community Medicine, University of Texas Health Science Center at San Antonio/San Antonio, Texas/Etats-Unis (3 aut.); South Texas Veterans' Health System, Audie L. Murphy Division GRECC/San Antonio, Texas/Etats-Unis (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2011; Vol. 26; No. 7; Pp. 1218-1224; Bibl. 31 ref.</SO>
<LA>Anglais</LA>
<EA>Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac <sup>123</sup>
I-metaiodobenzylguanidine uptake in Lewy body-related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered <sup>123</sup>
I-metaiodobenzylguanidine cardiac scintigraphy a "supportive" diagnostic feature, based on limited evidence. We report a meta-analysis of the literature and an assessment of the utility of <sup>123</sup>
I-metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty-six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed-effects regression model was used to analyze the delayed mean heart-to-mediastinum ratio of <sup>123</sup>
I-metaiodobenzylguanidine uptake. <sup>123</sup>
I-metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder ; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart-to-mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. <sup>123</sup>
I-metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies.</EA>
<CC>002B17; 002B17G</CC>
<FD>Démence à corps de Lewy; Maladie de Parkinson; Atrophie multisystématisée; Démence d'Alzheimer; Pathologie du   système nerveux; Scintigraphie; Diagnostic; Corps Lewy; Parasomnie</FD>
<FG>Pathologie de l'encéphale; Maladie dégénérative; Pathologie du   système nerveux central; Syndrome extrapyramidal; Trouble du sommeil; Trouble neurologique</FG>
<ED>Lewy body dementia; Parkinson disease; Multiple system atrophy; Alzheimer disease; Nervous system diseases; Scintigraphy; Diagnosis; Lewy body; Parasomnia</ED>
<EG>Cerebral disorder; Degenerative disease; Central nervous system disease; Extrapyramidal syndrome; Sleep disorder; Neurological disorder</EG>
<SD>Demencia cuerpos Lewy; Parkinson enfermedad; Atrofia multisistematizada; Demencia Alzheimer; Sistema nervioso patología; Centelleografía; Diagnóstico; Cuerpo Lewy; Parasomnio</SD>
<LO>INIST-20953.354000190480410050</LO>
<ID>11-0321200</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000559 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000559 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0321200
   |texte=   Meta-Analysis of 123I-MIBG Cardiac Scintigraphy for the Diagnosis of Lewy Body-Related Disorders
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Meta-Analysis of 123I-MIBG Cardiac Scintigraphy for the Diagnosis of Lewy Body-Related Disorders

Meta-Analysis of 123I-MIBG Cardiac Scintigraphy for the Diagnosis of Lewy Body-Related Disorders

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri